FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385398145> ?p ?o ?g. }

• W4385398145 abstract "<h3>Introduction/Purpose</h3> Since becoming available in 2007, flow diverters introduced the principle of endovascular reconstruction of the parent artery and exclusion of the aneurysm from the blood circulation, which has revolutionized intracranial aneurysm treatment. Despite the overall positive results, a major concern of flow diverter implantation is possible ischemic and thromboembolic complications. To reduce material thrombogenicity, the PED Flex device underwent surface modification with covalently bonded phosphorylcholine to the surface of the implant, so called Shield Technology™. This technology has been shown to reduce thrombogenicity and promote endothelialization with earlier and thicker neointima formation but less hyperplasia. <h3>Materials and Methods</h3> Prospectively maintained neurointerventional databases at 10 high-volume U.S. medical centers were retrospectively reviewed between April 2021 (corresponding with the FDA approval of the PED Shield) and October 2021. Additionally, compassionate use cases between 2016 and 2020 were also included. All patients who underwent placement of a PED Shield for treatment of a ruptured or unruptured intracranial aneurysm were identified. Patients who underwent re-treatment of an intracranial aneurysm due to failed primary treatment method were also included. Patient demographics, information on aneurysm size, morphology, and location as well as procedural data including device(s) used, adjunctive coiling and/or balloon angioplasty performed, intraprocedural complications, patient angiographic and clinical outcome was collected. <h3>Results</h3> One hundred eighty patients were included (144 women) with 187 aneurysms. Nineteen aneurysms were ruptured. The patient’s mean age was 57 years (range 14-84 years). Most aneurysms were located along the ICA (n=154), specifically along the ophthalmic segment (n=73), wide-necked (n=154) and saccular in shape (n=114). Mean aneurysm size was 5.8 mm (1.5 - 22.3 mm). PED Shield deployment was technically successful in 177 cases (98.3%). Balloon angioplasty was performed in 24 cases (13.3%). Aneurysm stasis after device deployment was seen in 113 aneurysms (60.4%). No procedure-related major ischemic stroke or neurological death occurred. Transient ischemic attack was seen in 3 patients (1.7%). One patient suffered an intraparenchymal bleed on post-op day 11 and 1 patient had a minor stroke leading to overall permanent neurological morbidity of 1.1%. Three to 6-month follow up was available for 136 patients (75.6%) and showed complete aneurysm occlusion in 58%, near-complete occlusion in 19.9% and partial occlusion in 22.1%. Twelve to 18-month follow up was available for 67 patients (37.2%). Complete occlusion was seen in 53.7%, near complete occlusion in 31% and partial occlusion in 14.9%. In total, up to 18-month follow-up was available for 143 patients (79.4%) and showed complete or near complete occlusion in 79%. Five patients have been retreated thus far (2.8%). <h3>Conclusion</h3> Our study is the first to report the early experience with the newly FDA-approved PED Flex with Shield technology amongst US centers. Our results are comparable with non-US, international studies showing a high technical success rate and safe peri-procedural angiographic and patient outcome. Longer follow-up will be needed to provide more robust data on angiographic and patient outcomes. <h3>Disclosures</h3> <b>A. Kuhn:</b> None. <b>J. Singh:</b> None. <b>A. Abdelsalam:</b> None. <b>V. Saini:</b> None. <b>J. Burks:</b> None. <b>G. Cortez:</b> None. <b>R. Abbas:</b> None. <b>M. Pervez:</b> None. <b>H. Saei:</b> None. <b>S. Burke:</b> None. <b>M. Salem:</b> None. <b>J. Vivanco-Suarez:</b> None. <b>R. Kutcher-Diaz:</b> None. <b>M. Bounajem:</b> None. <b>V. Naragum:</b> None. <b>F. Massari:</b> None. <b>S. Marwah:</b> None. <b>M. Gounis:</b> None. <b>A. Hassan:</b> 1; C; GE Healthcare and Valley Baptist. 2; C; Medtronic, Microvention, Stryker, Penumbra, Cerenovus, Genentech, GE Healthcare, Scientia, Balt, Viz.ai, Insera therapeutics, Proximie, NeuroVasc, NovaSignal, Vesalio, Rapid Medical, Imperative Care a. <b>A. Malek:</b> 2; C; CereVasc Inc.. 4; C; CereVasc Inc. <b>G. Dabus:</b> 2; C; Medtronic, Microvention, Cerenovus, Penumbra, Stryker, InNeuroCo, Route 92. <b>I. Linfante:</b> 2; C; Medtronic, Cerenovus. 4; C; InNeuroCo, Deinde, Prometeous, Three Rivers, Prolong Pharmaceuticals. <b>S. Tjoumakaris:</b> 2; C; Medtronic and Microvention (funds paid to institution, not personally). <b>P. Jabbour:</b> 2; C; Medtronic, Microvention and Cerus. <b>J. Burkhardt:</b> None. <b>B. Jankowitz:</b> None. <b>F. Mudassir:</b> None. <b>S. Ortega Gutierrez:</b> None. <b>R. Grandhi:</b> None. <b>R. Hanel:</b> 1; C; NIH, Interline Endowment, Microvention, Stryker and CNX. 2; C; Medtronic, Balt, Stryker, Q’Apel medical, Codman Neuro (J&J), Cerenovus, Microvention, Imperative Care, Phenox and Rapid Medical. <b>R. Starke:</b> 1; C; NREF, Joe Niekro Foundation, Brain Aneurysm Foundation, Bee Foundation, and by National Institute of Health, Medtronic. 2; C; Penumbra, Abbott, Medtronic, Balt, InNeuroCo, Cerenovus, Naglreiter and Optimize Vascular. <b>A. Puri:</b> 1; C; NIH, Microvention, Cerenovus, Medtronic Neurovascular and Stryker Neurovascular. 2; C; Medtronic Neurovascular, Stryker NeurovascularBalt, Q’Apel Medical, Cerenovus, Microvention, Imperative Care, Agile, Merit, CereVasc and Arsenal Medical. 4; C; InNeuroCo, Agile, Perfuze, Galaxy and NTI." @default.
• W4385398145 created "2023-07-31" @default.
• W4385398145 creator A5005530966 @default.
• W4385398145 creator A5008384414 @default.
• W4385398145 creator A5012979601 @default.
• W4385398145 creator A5014450486 @default.
• W4385398145 creator A5015547823 @default.
• W4385398145 creator A5020957307 @default.
• W4385398145 creator A5022960844 @default.
• W4385398145 creator A5030396271 @default.
• W4385398145 creator A5031553632 @default.
• W4385398145 creator A5031762120 @default.
• W4385398145 creator A5032682981 @default.
• W4385398145 creator A5033980806 @default.
• W4385398145 creator A5039726020 @default.
• W4385398145 creator A5040887464 @default.
• W4385398145 creator A5046638368 @default.
• W4385398145 creator A5047995039 @default.
• W4385398145 creator A5050468515 @default.
• W4385398145 creator A5052365969 @default.
• W4385398145 creator A5053752894 @default.
• W4385398145 creator A5055424750 @default.
• W4385398145 creator A5059562100 @default.
• W4385398145 creator A5063795761 @default.
• W4385398145 creator A5067280883 @default.
• W4385398145 creator A5067768492 @default.
• W4385398145 creator A5079068713 @default.
• W4385398145 creator A5079146238 @default.
• W4385398145 creator A5081631375 @default.
• W4385398145 creator A5082857375 @default.
• W4385398145 creator A5085650595 @default.
• W4385398145 creator A5085862615 @default.
• W4385398145 creator A5087784083 @default.
• W4385398145 creator A5088936912 @default.
• W4385398145 date "2023-07-01" @default.
• W4385398145 modified "2023-10-01" @default.
• W4385398145 title "O-063 First U.S. multicenter experience using the pipeline flex embolization device with shield technology for treatment of intracranial aneurysms" @default.
• W4385398145 doi "https://doi.org/10.1136/jnis-2023-snis.63" @default.
• W4385398145 hasPublicationYear "2023" @default.
• W4385398145 type Work @default.
• W4385398145 citedByCount "0" @default.
• W4385398145 crossrefType "proceedings-article" @default.
• W4385398145 hasAuthorship W4385398145A5005530966 @default.
• W4385398145 hasAuthorship W4385398145A5008384414 @default.
• W4385398145 hasAuthorship W4385398145A5012979601 @default.
• W4385398145 hasAuthorship W4385398145A5014450486 @default.
• W4385398145 hasAuthorship W4385398145A5015547823 @default.
• W4385398145 hasAuthorship W4385398145A5020957307 @default.
• W4385398145 hasAuthorship W4385398145A5022960844 @default.
• W4385398145 hasAuthorship W4385398145A5030396271 @default.
• W4385398145 hasAuthorship W4385398145A5031553632 @default.
• W4385398145 hasAuthorship W4385398145A5031762120 @default.
• W4385398145 hasAuthorship W4385398145A5032682981 @default.
• W4385398145 hasAuthorship W4385398145A5033980806 @default.
• W4385398145 hasAuthorship W4385398145A5039726020 @default.
• W4385398145 hasAuthorship W4385398145A5040887464 @default.
• W4385398145 hasAuthorship W4385398145A5046638368 @default.
• W4385398145 hasAuthorship W4385398145A5047995039 @default.
• W4385398145 hasAuthorship W4385398145A5050468515 @default.
• W4385398145 hasAuthorship W4385398145A5052365969 @default.
• W4385398145 hasAuthorship W4385398145A5053752894 @default.
• W4385398145 hasAuthorship W4385398145A5055424750 @default.
• W4385398145 hasAuthorship W4385398145A5059562100 @default.
• W4385398145 hasAuthorship W4385398145A5063795761 @default.
• W4385398145 hasAuthorship W4385398145A5067280883 @default.
• W4385398145 hasAuthorship W4385398145A5067768492 @default.
• W4385398145 hasAuthorship W4385398145A5079068713 @default.
• W4385398145 hasAuthorship W4385398145A5079146238 @default.
• W4385398145 hasAuthorship W4385398145A5081631375 @default.
• W4385398145 hasAuthorship W4385398145A5082857375 @default.
• W4385398145 hasAuthorship W4385398145A5085650595 @default.
• W4385398145 hasAuthorship W4385398145A5085862615 @default.
• W4385398145 hasAuthorship W4385398145A5087784083 @default.
• W4385398145 hasAuthorship W4385398145A5088936912 @default.
• W4385398145 hasConcept C126838900 @default.
• W4385398145 hasConcept C141071460 @default.
• W4385398145 hasConcept C2776035437 @default.
• W4385398145 hasConcept C2776098176 @default.
• W4385398145 hasConcept C2776649359 @default.
• W4385398145 hasConcept C2777339539 @default.
• W4385398145 hasConcept C2777793317 @default.
• W4385398145 hasConcept C2778283817 @default.
• W4385398145 hasConcept C2778583881 @default.
• W4385398145 hasConcept C2780868729 @default.
• W4385398145 hasConcept C71924100 @default.
• W4385398145 hasConceptScore W4385398145C126838900 @default.
• W4385398145 hasConceptScore W4385398145C141071460 @default.
• W4385398145 hasConceptScore W4385398145C2776035437 @default.
• W4385398145 hasConceptScore W4385398145C2776098176 @default.
• W4385398145 hasConceptScore W4385398145C2776649359 @default.
• W4385398145 hasConceptScore W4385398145C2777339539 @default.
• W4385398145 hasConceptScore W4385398145C2777793317 @default.
• W4385398145 hasConceptScore W4385398145C2778283817 @default.
• W4385398145 hasConceptScore W4385398145C2778583881 @default.
• W4385398145 hasConceptScore W4385398145C2780868729 @default.
• W4385398145 hasConceptScore W4385398145C71924100 @default.
• W4385398145 hasLocation W43853981451 @default.
• W4385398145 hasOpenAccess W4385398145 @default.
• W4385398145 hasPrimaryLocation W43853981451 @default.
• W4385398145 hasRelatedWork W17100482 @default.

• next